146 related articles for article (PubMed ID: 25202262)
1. Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung? A Case Report.
Aroldi F; Bertocchi P; Meriggi F; Abeni C; Ogliosi C; Rota L; Zambelli C; Bnà C; Zaniboni A
Case Rep Oncol; 2014 May; 7(2):478-83. PubMed ID: 25202262
[TBL] [Abstract][Full Text] [Related]
2. Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with
Muto S; Ozaki Y; Okabe N; Matsumura Y; Hasegawa T; Shio Y; Hashimoto Y; Suzuki H
Case Rep Oncol; 2020; 13(3):1387-1392. PubMed ID: 33442360
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
[TBL] [Abstract][Full Text] [Related]
4. A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an EGFR mutation: A case report.
Wang Y; Shen YH; Ma S; Zhou J
Oncol Lett; 2015 Sep; 10(3):1575-1578. PubMed ID: 26622712
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Yokoyama Y; Sonobe M; Yamada T; Sato M; Menju T; Aoyama A; Sato T; Chen F; Omasa M; Date H
Int J Clin Oncol; 2015 Dec; 20(6):1122-9. PubMed ID: 25953679
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
8. Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literature.
Sakai Y; Yamasaki T; Kusakabe Y; Kasai D; Kotani Y; Nishimura Y; Itoh T
Multidiscip Respir Med; 2013 Jul; 8(1):47. PubMed ID: 23866929
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS; Kobayashi S; Costa DB
Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
[TBL] [Abstract][Full Text] [Related]
10. Transformation to large cell neuroendocrine carcinoma as acquired resistance mechanism of EGFR tyrosine kinase inhibitor.
Kogo M; Shimizu R; Uehara K; Takahashi Y; Kokubo M; Imai Y; Tomii K
Lung Cancer; 2015 Nov; 90(2):364-8. PubMed ID: 26384434
[TBL] [Abstract][Full Text] [Related]
11. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
12. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M
J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502
[TBL] [Abstract][Full Text] [Related]
13. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
[TBL] [Abstract][Full Text] [Related]
14. Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma.
Iyoda A; Travis WD; Sarkaria IS; Jiang SX; Amano H; Sato Y; Saegusa M; Rusch VW; Satoh Y
Exp Ther Med; 2011 Nov; 2(6):1041-1045. PubMed ID: 22977617
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
Uchibori K; Satouchi M; Sueoka-Aragane N; Urata Y; Sato A; Imamura F; Inoue T; Tachihara M; Kobayashi K; Katakami N; Kokan C; Hirashima T; Iwanaga K; Mori M; Aoe K; Morita S; Negoro S
Lung Cancer; 2018 Oct; 124():65-70. PubMed ID: 30268482
[TBL] [Abstract][Full Text] [Related]
16. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
17. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of gefitinib during pregnancy: case report and literature review.
Gil S; Goetgheluck J; Paci A; Broutin S; Friard S; Couderc LJ; Ayoubi JM; Picone O; Tcherakian C
Lung Cancer; 2014 Sep; 85(3):481-4. PubMed ID: 24997732
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
[TBL] [Abstract][Full Text] [Related]
20. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]